Compare Bristol-Myers Squibb Co (BMY) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Krispy Kreme Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.82 (market cap $132.45B), while Krispy Kreme Inc trades at $3.13 (market cap $544.79M). The key difference: Bristol-Myers Squibb Co is far larger — about 243.1× Krispy Kreme Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | DNUT | |
|---|---|---|
Market Cap | $132.45B | $544.79M |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $4.70 |
52-Week Low | $42.60 | $2.92 |
Enterprise Value | $166.44B | $1.79B |
Dividend Yield | 3.89% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
Krispy Kreme (DNUT) trades at $3.34, up 3.41% today, with a bullish technical signal from oscillators and mixed earnings history. The company reported a net loss of -$515.77M in 2025 but shows margin improvement and a capital-light refranchising strategy. Recent news highlights a turnaround focus, with the CEO affirming progress on profitability and leverage reduction.
Outlook hinges on execution of the turnaround plan; opportunities include international expansion and cost controls, but risks persist from high debt and competitive pressures. Analysts are cautiously optimistic with a 50% buy rating, though negative profitability metrics warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
